Assessing the Efficacy of ICIs in TNBC Using Immune Cellular and Metabolic Profiles
FDA Approves Amivantamab Plus Carboplatin, Pemetrexed For Certain Patients With NSCLC
A First-of-its-Kind Machine Learning Model to Flag, Screen People for Elevated Lipoprotein(a)